Wegovy via subscription

Novo Nordisk started a subscription program for Wegovy on March 31, routing cash-pay patients through telehealth companies instead of a traditional pharmacy search. (managedhealthcareexecutive.com) The first partners are Ro, WeightWatchers and LifeMD, and Novo Nordisk said Hims & Hers and Sesame are expected to join later. The company called it its first multi-month subscription program for Food and Drug Administration-approved Wegovy. (managedhealthcareexecutive.com) (novonordisk-us.com) Ro said the program offers 3-, 6- and 12-month prepaid plans and can cut costs by as much as $1,200 a year for the Wegovy pen or $600 a year for the Wegovy pill. Novo Nordisk has framed the pitch as a lower, predictable monthly price for eligible self-pay patients. (ro.co) (novonordisk-us.com) Wegovy is semaglutide, a glucagon-like peptide-1 drug that helps people lose weight and is also approved to cut the risk of major cardiovascular events in some adults with obesity or overweight. The Food and Drug Administration label says it is used with a reduced-calorie diet and increased physical activity. (accessdata.fda.gov 1) (accessdata.fda.gov 2) The timing follows Novo Nordisk’s push to steer patients toward branded, Food and Drug Administration-approved semaglutide as compounders and telehealth sellers expanded during shortages. Novo Nordisk’s United States site now pairs the subscription announcement with warnings about compounded and counterfeit semaglutide. (novonordisk-us.com) (managedhealthcareexecutive.com) Novo Nordisk has also been widening its direct cash-pay offers through NovoCare Pharmacy. Its current pricing pages say new patients can pay $199 a month for the 0.25 milligram and 0.5 milligram doses for two fills through June 30, 2026, while some higher-dose pill offers are listed at $149 a month for a limited period. (novocare.com) (wegovy.com) The program arrives as Wegovy itself expands beyond weekly injections. Food and Drug Administration labeling posted in 2026 shows an oral Wegovy tablet is approved for weight reduction and cardiovascular risk reduction in eligible adults. (accessdata.fda.gov) The immediate effect is simpler shopping: a patient who already has, or gets, a Wegovy prescription through one of these telehealth services can lock in pricing over several months instead of paying month to month. Novo Nordisk is betting that steadier pricing and telehealth distribution will keep more patients on its branded drug. (ro.co) (managedhealthcareexecutive.com)